LB Pharmaceuticals Common Stock
LBRX | NASDAQ
$42.16
-$0.83 (-1.93%)
Sep 22, 2026, 2:09 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 |
|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a |
Operating Income | -30.4M | -64.83M | -11.38M | -2.81M |
Interest Income | 3.92M | 1.72M | 811K | 73K |
Pretax Income | -25.2M | -63.1M | -6.27M | -14.35M |
Net Income | -25.21M | -63.1M | -6.28M | -14.35M |
Selling & General & Admin | 13.66M | 13.66M | 3.53M | 1.46M |
Research & Development | 16.74M | 51.17M | 7.85M | 1.35M |
Other Expenses | n/a | n/a | n/a | n/a |
Operating Expenses | 30.4M | 64.83M | 11.38M | 2.81M |
Interest Expense | n/a | n/a | 4.83M | 2.15M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 30.4M | 64.83M | 11.38M | 2.81M |
Income Tax Expense | 1K | 1K | 1K | 1K |
Shares Outstanding (Basic) | 25.3M | 3.54M | 3.54M | 3.54M |
Shares Outstanding (Diluted) | 25.3M | 3.54M | 3.54M | 3.54M |
EPS (Basic) | -1 | -17.83 | -1.77 | -4.05 |
EPS (Diluted) | -1 | -17.83 | -1.77 | -4.05 |
EBITDA | -24.88M | -63.01M | -1.45M | -12.19M |
EBIT | -25.2M | -63.1M | -1.45M | -12.2M |
Depreciation & Amortization | 321K | 91K | 4K | 2K |
Add to Watchlist
Select watchlists to add or remove LBRX